Date:7/25/2011

's revenue expectations for AmnioFix™ and EpiFix® in the third and fourth quarters of 2011 and the Company's expectations for quarter over quarter increases in its wound care revenue; the Company's OEM business opportunities and its ability to bring OEM relationships online during the third quarter; the Company's ability to achieve EBITDA break even in the third quarter; the prospect of receiving the CE Mark regulatory clearance for the Company's CollaFix™ product during the third quarter and the prospects for other regulatory approvals for the Company's collagen products in Europe and the United States; the upcoming demands for the Company's collagen fiber and potential for the Company's manufacturing capabilities to meet those demands; and the completion of the Company's operational consolidations by the end of the third quarter. These statements are based on current information and belief, and are not guarantees of future performance.  Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the expected clinical, quality and cost impact of the Company's tissue offerings may not be realized; that the market opportunities for the Company's amniotic tissue technology may fail to materialize; that the Company may fail to achieve its revenue expectations for AmnioFix™ and EpiFix® in the third and fourth quarters of 2011 or may not achieve the expected quarter over quarter increases in wound care revenue; that the OEM business opportunities may not materialize as expected and the Company may be unable to bring OEM relationships online during the third quarter; that the Company may not be able to achieve or sustain EBITDA breakeven or profitability; that the Company may not receive anticipated regulatory clearances and/or approvals or that such clearances or approvals may be delayed; that the Company may not be successful in ramping up its
'/>"/>

SOURCE MiMedx, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related biology technology :

1. MiMedx Group, Inc. Announces Release Date for Second Quarter Results
2. MiMedx Group Completes $5,000,000 Private Placement
3. MiMedx Group, Inc. to Present at the Noble Financial Capital Markets Seventh Annual Equity Conference
4. MiMedx Group Announces First Quarter 2011 Results
5. MiMedx Group Announces 2010 Results
6. MiMedx Group, Inc. to Present at the 10th Annual Needham Healthcare Conference
7. MiMedx Announces Launch of AmnioFix™
8. MiMedx to Attend American Academy of Orthopedic Surgeons Annual Meeting
9. MiMedx Group, Inc. to Present at the 13th Annual Needham Growth Conference
10. MiMedx Group, Inc. Announces Release Date For Third Quarter Results
11. MiMedx Group, Inc. to Present at Noble Financial Sixth Annual Equity Conference